Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Abstract Alzheimer's Disease (AD), the most prevalent neurodegenerative disease of aging,
affects one in eight older Americans. Nearly all drug treatments tested for AD today have …

Abstract γ-Secretase is a fascinating, multi-subunit, intramembrane cleaving protease that is
now being considered as a therapeutic target for a number of diseases. Potent, orally …

Alzheimer's disease (AD) is a neurodegenerative disease, characterized by progressive loss
of memory which is associated with other cognitive deficits. The two protein structures in the …

Alzheimer's disease (AD) is a neurodegenerative disorder linked to protein misfolding and
aggregation. AD is pathologically characterized by senile plaques formed by extracellular …

The endosome/lysosome pathway is disrupted early in the course of both Alzheimer's
disease (AD) and Down syndrome (DS); however, it is not clear how dysfunction in this …

Abstract γ‐Secretase inhibitors (GSI s) are being actively repurposed as cancer therapeutics
based on the premise that inhibition of NOTCH 1 signaling in select cancers is therapeutic …

Axonal transport deficits in Alzheimer's disease (AD) are attributed to amyloid β (Aβ)
peptides and pathological forms of the microtubule-associated protein tau. Genetic ablation …

The rapidly aging population desperately requires new therapies for Alzheimer's disease.
Despite years of pharmaceutical research, limited clinical success has been realized, with …

Notch1-4 receptors and their signaling pathways are expressed in almost all organ systems
and play a pivotal role in cell fate decision by coordinating cell proliferation, differentiation …